There is considerable interest in NMDAR modulators to enhance memory and treat neuropsychiatric disorders such as addiction,depression, and schizophrenia.D-serine and D-cycloserine, the NMDAR activators at the glycine site, are of particular interest because theyhave been used in humans without serious adverse effects.
Our results indicate that HA-NMDAR modulators can reduce aversion-resistant alcohol drinking, and support testing ofD-serine and D-cycloserine asi mmediately accessible, FDA-approved drugs to treat AUDs.
Source: